Miltefosine is an alkylphosphocholine drug with demonstrated activity against various parasite
species and cancer cells as well as some pathogenic bacteria and fungi. For 10 years it …

Artemisinin and its derivatives are renowned for their potent antimalarial activity. They have
found their way into clinical use in many areas where malaria is endemic. The in vitro …

Background Chloroquine remains the mainstay of treatment for Plasmodium vivax malaria
despite increasing reports of treatment failure. We did a systematic review and meta-analysis …

The pharmacokinetics of miltefosine in leishmaniasis patients are, to a great extent, unknown.
We examined and characterized the pharmacokinetics of miltefosine in a group of patients …

Parasite clearance data from 18,699 patients with falciparum malaria treated with an artemisinin
derivative in areas of low (n = 14,539), moderate (n = 2077), and high (n = 2083) levels …

Current SARS-CoV-2 vaccines are losing efficacy against emerging variants and may not
protect against future novel coronavirus outbreaks, emphasizing the need for more broadly …

Background. Recent reports indicated high miltefosine treatment failure rates for visceral
leishmaniasis (VL) on the Indian subcontinent. To further explore the pharmacological factors …

Background This study aims to estimate the age-specific risks of clinical dengue attack (ie,
the risk of symptomatic dengue among the total number of dengue virus (DENV) infections) …

Only anecdotal data are available on the pharmacokinetics (PK) of miltefosine in children
suffering from visceral leishmaniasis (VL). While failure rates were higher in children with VL, …

Background Leishmaniasis is increasingly reported among travellers. Leishmania species
vary in sensitivity to available therapies. Fast and reliable molecular techniques have made …